{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:11:11Z","timestamp":1790838671312,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2004,12,6]],"date-time":"2004-12-06T00:00:00Z","timestamp":1102291200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Ciprofloxacin is effective in perianal Crohn's disease but after treatment discontinuation symptoms reoccur. Infliximab is effective but requires maintenance therapy.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To evaluate the effect of combined ciprofloxacin and infliximab in perianal Crohn's disease.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002A double\u2010blind placebo\u2010controlled study was conducted. Patients were randomly assigned to receive 500\u2010mg ciprofloxacin twice daily or a placebo for 12\u2003weeks. All patients received 5\u2010mg\/kg infliximab in week 6, 8 and 12 and were followed for 18\u2003weeks. Primary end\u2010point was clinical response, defined as a 50% or greater reduction from baseline in the number of draining fistulae. Secondary end\u2010points were the change in Perianal Disease Activity Index and hydrogen peroxide enhanced three\u2010dimensional endoanal ultrasonography findings. Analysis was by intention\u2010to\u2010treat.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Twenty\u2010four patients were included but two discontinued treatment. At week 18, response was 73% (eight of 11) in the ciprofloxacin group and 39% (five of 13) in the placebo group (<jats:italic>P<\/jats:italic>\u2003=\u20030.12). Using logistic regression analysis patients treated with ciprofloxacin tended to respond better (OR\u2003=\u20032.37, CI: 0.94\u20135.98, <jats:italic>P<\/jats:italic>\u2003=\u20030.07). The Perianal Disease Activity Index score only improved (<jats:italic>P<\/jats:italic>\u2003=\u20030.008) in the ciprofloxacin group. Three\u2010dimensional endoanal ultrasonography improved in three patients with a clinical response.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002A combination of ciprofloxacin and infliximab tended to be more effective than infliximab alone.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02247.x","type":"journal-article","created":{"date-parts":[[2004,12,10]],"date-time":"2004-12-10T13:26:26Z","timestamp":1102685186000},"page":"1329-1336","source":"Crossref","is-referenced-by-count":218,"title":["Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double\u2010blind placebo\u2010controlled study"],"prefix":"10.1111","volume":"20","author":[{"given":"R. L.","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. F.","family":"Felt\u2010Bersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. P.","family":"van Tilburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. G.","family":"Drapers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,12,6]]},"reference":[{"key":"e_1_2_18_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00392-5"},{"key":"e_1_2_18_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2003.08.025"},{"key":"e_1_2_18_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(80)90402-3"},{"key":"e_1_2_18_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(82)80332-6"},{"key":"e_1_2_18_6_2","first-page":"533","article-title":"Metronidazole therapy for Crohn's disease and associated fistulae","volume":"79","author":"Jakobovits J","year":"1984","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_18_7_2","first-page":"144","article-title":"Long\u2010term treatment of perianal or fistulous Crohn's disease with ciprofloxacin","volume":"24","author":"Turunen U","year":"1989","journal-title":"Scand J Gastroenerol"},{"key":"e_1_2_18_8_2","first-page":"A212","article-title":"Ciprofloxacin may be useful in Crohn's disease (abstract)","volume":"98","author":"Wolf J.","year":"1990","journal-title":"Gastroenterology"},{"key":"e_1_2_18_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/1993\/610272"},{"key":"e_1_2_18_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_18_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_18_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"e_1_2_18_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01427.x"},{"key":"e_1_2_18_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6111-6"},{"key":"e_1_2_18_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04009.x"},{"key":"e_1_2_18_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199501000-00008"},{"key":"e_1_2_18_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800630102"},{"key":"e_1_2_18_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01793.x"},{"key":"e_1_2_18_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03363.x"},{"key":"e_1_2_18_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03366.x"},{"key":"e_1_2_18_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03612.x"},{"key":"e_1_2_18_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.07093.x"},{"key":"e_1_2_18_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200303000-00003"},{"key":"e_1_2_18_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200403000-00005"},{"key":"e_1_2_18_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6758-z"},{"key":"e_1_2_18_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31072"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02247.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02247.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02247.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T18:35:26Z","timestamp":1693420526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02247.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":25,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02247.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02247.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}